Collegium Pharmaceutical Debt-to-Equity Ratio Growth & History (COLL)
Collegium Pharmaceutical's debt-to-equity ratio was 0.02 for fiscal 2025.
View full Collegium Pharmaceutical company overviewCollegium Pharmaceutical annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.02 | −0.01 | −38.30% |
| 2024 | 2024-12-31 | 0.03 | −0.01 | −18.23% |
| 2023 | 2023-12-31 | 0.04 | −0.01 | −13.78% |
| 2022 | 2022-12-31 | 0.04 | −0.00 | −2.28% |
| 2021 | 2021-12-31 | 0.04 | −0.01 | −15.37% |
| 2020 | 2020-12-31 | 0.05 | −0.20 | −79.33% |
| 2019 | 2019-12-31 | 0.25 | 0.12 | +96.69% |
| 2018 | 2018-12-31 | 0.13 | — | — |
| 2016 | 2016-12-31 | 0.03 | −0.05 | −61.63% |
| 2015 | 2015-12-31 | 0.08 | — | — |
Collegium Pharmaceutical quarterly debt-to-equity ratio
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.02 | −0.01 | −40.26% |
| Q1 2026 | 2026-03-31 | 0.02 | −0.01 | −39.58% |
| Q4 2025 | 2025-12-31 | 0.02 | −0.01 | −38.30% |
| Q3 2025 | 2025-09-30 | 0.02 | −0.01 | −30.32% |
| Q2 2025 | 2025-06-30 | 0.03 | −0.00 | −12.92% |
| Q1 2025 | 2025-03-31 | 0.03 | −0.00 | −10.33% |
| Q4 2024 | 2024-12-31 | 0.03 | −0.01 | −18.23% |
| Q3 2024 | 2024-09-30 | 0.03 | −0.01 | −25.33% |
| Q2 2024 | 2024-06-30 | 0.03 | −0.01 | −19.12% |
| Q1 2024 | 2024-03-31 | 0.03 | −0.01 | −29.75% |
| Q4 2023 | 2023-12-31 | 0.04 | −0.01 | −13.78% |
| Q3 2023 | 2023-09-30 | 0.04 | −0.00 | −5.00% |
| Q2 2023 | 2023-06-30 | 0.04 | −0.01 | −15.10% |
| Q1 2023 | 2023-03-31 | 0.04 | −0.00 | −5.02% |
| Q4 2022 | 2022-12-31 | 0.04 | −0.00 | −2.28% |
| Q3 2022 | 2022-09-30 | 0.04 | 0.01 | +21.18% |
| Q2 2022 | 2022-06-30 | 0.04 | 0.01 | +23.43% |
| Q1 2022 | 2022-03-31 | 0.05 | −0.01 | −15.41% |
| Q4 2021 | 2021-12-31 | 0.04 | −0.01 | −15.37% |
| Q3 2021 | 2021-09-30 | 0.04 | −0.02 | −36.26% |
| Q2 2021 | 2021-06-30 | 0.04 | −0.03 | −42.46% |
| Q1 2021 | 2021-03-31 | 0.05 | −0.02 | −22.20% |
| Q4 2020 | 2020-12-31 | 0.05 | −0.20 | −79.33% |
| Q3 2020 | 2020-09-30 | 0.06 | −0.20 | −78.42% |
| Q2 2020 | 2020-06-30 | 0.06 | −0.19 | −75.55% |
| Q1 2020 | 2020-03-31 | 0.07 | −0.19 | −72.49% |
| Q4 2019 | 2019-12-31 | 0.25 | 0.12 | +96.69% |
| Q3 2019 | 2019-09-30 | 0.26 | 0.10 | +59.70% |
| Q2 2019 | 2019-06-30 | 0.26 | 0.12 | +84.60% |
| Q1 2019 | 2019-03-31 | 0.26 | 0.13 | +102.26% |
| Q4 2018 | 2018-12-31 | 0.13 | — | — |
| Q3 2018 | 2018-09-30 | 0.16 | — | — |
| Q2 2018 | 2018-06-30 | 0.14 | — | — |
| Q1 2018 | 2018-03-31 | 0.13 | — | — |
| Q4 2016 | 2016-12-31 | 0.03 | −0.05 | −61.63% |
| Q4 2015 | 2015-12-31 | 0.08 | — | — |
Collegium Pharmaceutical debt-to-equity ratio trends
Over the last five fiscal years, Collegium Pharmaceutical's debt-to-equity ratio decreased from 0.05 to 0.02, a change of −0.03. The latest reported quarter, Q2 2026, shows 0.02.
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Collegium Pharmaceutical source filings ↗